European Investment Bank provides €125 million loan to Orano Med for nuclear medicine cancer treatment project
Application
Originally reported by ccnta.cn
The European Investment Bank (EIB) has signed a €125 million credit facility with Orano, earmarked for its nuclear medicine subsidiary Orano Med. The funding will support the construction of the Advanced Thorium Extraction Facility (ATEF) in Bessines-sur-Gartempe, France, which is described as the world's first industrial-scale plant dedicated to producing thorium-228. Thorium-228 is a precursor for lead-212, a critical radioisotope used in targeted alpha therapy for cancer. The ATEF facility, which broke ground in November 2024 and is slated for commissioning in 2027, represents a total investment of approximately €250 million and is expected to create nearly 70 direct and 100 indirect jobs.
This financing is significant not for additive manufacturing, but for the broader deep-tech and nuclear medicine supply chain. Orano Med is developing lead-212-based targeted alpha therapies, with four active clinical programs covering multiple cancer types with high unmet medical need. The company collaborates with major pharmaceutical partners including Sanofi, Roche, and Swiss biotech firm Molecular Partners. The EIB loan, alongside €22 million in public support from France's '2030 Plan,' underscores European strategic efforts to secure domestic production capacity for critical medical isotopes, reducing reliance on foreign supply chains. This mirrors the kind of infrastructure and qualification discipline seen in aerospace AM: building repeatable, certified production capacity rather than relying on demonstration-scale facilities.
From an industrial policy perspective, this is a concrete step toward vertical integration of the lead-212 therapy supply chain, with Orano Med controlling thorium-228 extraction, isotope processing, and drug manufacturing across facilities in France and the United States. The company must now execute on ATEF's construction timeline and clinical trial milestones to validate the economics of centralized isotope production. For the nuclear medicine field, this represents a shift from lab-scale isotope generation toward industrial-scale manufacturing, a transition that will determine whether targeted alpha therapy can achieve the commercial scale and cost profile needed for broad patient access.
Topics